Clinical Trial Update: Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation [Phase 3]

View source ↗

Summary

Phase 3 randomized trial evaluating anti-thymocyte globulin (ATG) for prevention of graft-versus-host disease in pediatric patients receiving unrelated donor st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematologic Malignancies

Drugs mentioned

• Anti-thymocyte globulin (ATG) (anti-thymocyte globulin)

Snippet

Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia | Conditions: Paediatric Patients Affected by Haematological Malignancies and Eligible to Undergo HSCT From an Unrelated Volunteer | Phase 3 | Status: UNKNOWN